Clark Estates Inc. NY Increases Stake in Indivior PLC (NASDAQ:INDV)

Clark Estates Inc. NY grew its holdings in shares of Indivior PLC (NASDAQ:INDV) by 1.3% in the fourth quarter, HoldingsChannel reports. The fund owned 257,400 shares of the company’s stock after purchasing an additional 3,300 shares during the quarter. Clark Estates Inc. NY’s holdings in Indivior were worth $3,199,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in Indivior during the fourth quarter valued at about $56,000. Stifel Financial Corp bought a new stake in Indivior in the 3rd quarter valued at $100,000. Melqart Asset Management UK Ltd bought a new position in Indivior during the third quarter valued at approximately $132,000. Jane Street Group LLC bought a new position in shares of Indivior during the 3rd quarter valued at approximately $180,000. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Indivior in the third quarter valued at $294,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior Price Performance

Shares of INDV stock opened at $10.10 on Wednesday. The company has a market capitalization of $1.39 billion, a P/E ratio of -28.86 and a beta of 0.73. The company’s 50-day simple moving average is $11.06 and its two-hundred day simple moving average is $10.63. Indivior PLC has a one year low of $7.33 and a one year high of $22.53.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, hitting the consensus estimate of $0.32. The business had revenue of $298.00 million during the quarter, compared to analysts’ expectations of $262.35 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. On average, research analysts expect that Indivior PLC will post 1.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. RODMAN&RENSHAW upgraded shares of Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on Indivior in a report on Tuesday, January 28th. They set a “buy” rating and a $16.00 price target on the stock.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.